Uncategorized
Fovista combined with monthly Lucentis shows no benefit over anti-VEGF monotherapy
Ophthotech Corporation announced that Fovista did not meet its primary endpoint of mean change in visual acuity in two phase 3 clinical trials comparing combination treatment of Fovista, an anti-PDGF, plus Lucentis, an anti-VEGF, with Lucentis monotherapy alone for treatment of wet age-related macular edema. “We are very disappointed in the results from these trials, particularly for patients afflicted with wet AMD,” David R. Guyer, MD, chief executive officer of Ophthotech, said in a company press release, which reported that no benefit was observed when the anti-PDGF was added to (Read more...)